These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 27534768)

  • 21. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols.
    Yaqoubi S; Chan HK; Nokhodchi A; Dastmalchi S; Alizadeh AA; Barzegar-Jalali M; Adibkia K; Hamishehkar H
    Int J Pharm; 2021 Jun; 602():120568. PubMed ID: 33812969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Particle engineering in dry powders for inhalation.
    Scherließ R; Bock S; Bungert N; Neustock A; Valentin L
    Eur J Pharm Sci; 2022 May; 172():106158. PubMed ID: 35248734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
    Kolanjiyil AV; Kleinstreuer C; Sadikot RT
    Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges for pulmonary delivery of high powder doses.
    Sibum I; Hagedoorn P; de Boer AH; Frijlink HW; Grasmeijer F
    Int J Pharm; 2018 Sep; 548(1):325-336. PubMed ID: 29991452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of particle properties in pharmaceutical powder inhalation formulations.
    Chew NY; Chan HK
    J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver.
    Weers J; Ung K; Le J; Rao N; Ament B; Axford G; Maltz D; Chan L
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):56-68. PubMed ID: 22691109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of the solid state and physical properties of the carrier in adhesive mixtures for lung delivery.
    Della Bella A; Salomi E; Buttini F; Bettini R
    Expert Opin Drug Deliv; 2018 Jul; 15(7):665-674. PubMed ID: 28829232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Formulation of new generation drug delivery system for dry powder inhalation.].
    Chvatal A; Szabo B; Szabo-Revesz P; Ambrus R
    Acta Pharm Hung; 2016; 86(3):75-83. PubMed ID: 29489079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
    Momin MAM; Tucker IG; Das SC
    Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Acoustic-Based Method to Detect and Quantify the Effect of Exhalation into a Dry Powder Inhaler.
    Holmes MS; Seheult JN; O'Connell P; D'Arcy S; Ehrhardt C; Healy AM; Costello RW; Reilly RB
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):247-53. PubMed ID: 25393346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current Inhalers Deliver Very Small Doses to the Lower Tracheobronchial Airways: Assessment of Healthy and Constricted Lungs.
    Walenga RL; Longest PW
    J Pharm Sci; 2016 Jan; 105(1):147-59. PubMed ID: 26852850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formulation Design of Dry Powders for Inhalation.
    Weers JG; Miller DP
    J Pharm Sci; 2015 Oct; 104(10):3259-88. PubMed ID: 26296055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review.
    Tong Z; Yu A; Chan HK; Yang R
    Curr Pharm Des; 2015; 21(27):3966-73. PubMed ID: 26290194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing Dry Powder Inhaler Formulations.
    Morton DAV; Barling D
    J Aerosol Med Pulm Drug Deliv; 2024 Apr; 37(2):90-99. PubMed ID: 38640447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Respiratory Tract: Structure and Attractions for Drug Delivery Using Dry Powder Inhalers.
    ElKasabgy NA; Adel IM; Elmeligy MF
    AAPS PharmSciTech; 2020 Aug; 21(7):238. PubMed ID: 32827062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.